- Home
- IMTX vs ODTX Comparison
IMTX vs ODTX Comparison
Compare IMTX & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | ODTX |
|---|---|---|
| Founded | N/A | 2021 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IMTX | ODTX |
|---|---|---|
| Price | $7.32 | $19.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $17.26 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 1.0M | 238.2K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.65 | $15.10 |
| 52 Week High | $12.41 | $29.05 |
Technical Indicators
Market Signals| Indicator | IMTX | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 47.61 |
| Support Level | $6.65 | $15.73 |
| Resistance Level | $10.60 | $19.60 |
| Average True Range (ATR) | 0.40 | 1.37 |
| MACD | 0.07 | 0.25 |
| Stochastic Oscillator | 50.77 | 65.40 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About ODTX Odyssey Therapeutics Inc. Common Stock
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.